Current SATVI news
SATVI authors Dr Elisa Nemes, Prof Mark Hatherill, Associate Prof Tom Scriba, Dr Michele Tameris, Humphrey Mulenga and Danelle Van As have published a research paper titled: "Safety and Immunogenicity of newborn MVA 85 A vaccination and selective delayed Bacille Calmette-Guerin for infants of HIV infected mothers: a Phase 2 randomized controlled trial" appearing in the Infectious Disease Journal (Oxford).
Associate Professor Tom Scriba has co-authored a article titled: "Host blood RNA predict the outcome of tuberculosis treatment" appearing in the Tuberculosis Journal.
SATVI invites applications for the position of Research Officer: Systems Immunology at its Cape Town offices. CLOSED.
SATVI authors have published a research paper titled: "Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population" appearing in the PLoS ONE Journal.
Professor Mark Hatherill and Associate Professor Tom Scriba have co-authored a research paper titled "A Functional Toll-interacting Protein variant with Bacillus Calmette-Guerin specific immune responses and Tuberculosis" appearing in the American Journal of Respiratory and Critical Care Medicine.
Associate Professor Tom Scriba has co-authored a research paper titled "Identifying specificity groups in the T Cell receptor repertoire" appearing in the Nature Journal.
SATVI authors Associate Professor Tom Scriba, Dr Stanley Mbandi Kimbung, Fatoumatta Darboe and Dr Adam Penn-Nicholson have co-authored a paper titled "Protein kinase C-delta (PKCd), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice" appearing in the Mucosol Immunology Journal.
SATVI recently marked the 3 000th patient who had been screened for participation in the Correlates of Risk of TB study (CORTIS-01).
On Thursday 24 August 2017, the South African Tuberculosis Vaccine Initiative (SATVI) partnered with Ikamva Lethu, a women’s cooperative based in Worcester, in presenting a bead making workshop to learners at the Sinetemba Aftercare Centre in Zwelethemba, Worcester.
SATVI researcher Associate Professor Tom Scriba has co-authored a research paper titled: "The CSF Immune Response in HIV-1–Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy" appearing in the Journal of Acquired Immune Deficiency Syndrome.
South African Tuberculosis Vaccine Initiative (SATVI), located within Infectious Disease and Molecular Medicine (IDM) at the Faculty of Health Sciences invites applications from suitably qualified candidates for a 24-month contract position of Laboratory Technologist based in Worcester. CLOSED
SATVI authors have published research in which they find that the implementation of optimized procedures and a more rigorous QuantiFERON-TB conversion definition, an increase from IFNy<0.2 to >0.7 IU/mL, would allow more definitive detection of recent M.tb infection and potentially improve identification of those more likely to develop disease.